Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.

Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, Yakushigawa T, Sugiyama H, Shimada Y, Nojima Y, Shio N.

J Am Coll Cardiol. 2014 Feb 18;63(6):528-36. doi: 10.1016/j.jacc.2013.09.056. Epub 2013 Oct 30.

2.

Spironolactone for heart failure with preserved ejection fraction.

Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators.

N Engl J Med. 2014 Apr 10;370(15):1383-92. doi: 10.1056/NEJMoa1313731.

3.

Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study.

Lin C, Zhang Q, Zhang H, Lin A.

J Clin Hypertens (Greenwich). 2016 Feb;18(2):121-8. doi: 10.1111/jch.12628. Epub 2015 Jul 30.

4.

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J.

N Engl J Med. 1999 Sep 2;341(10):709-17.

5.

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators.

N Engl J Med. 2003 Apr 3;348(14):1309-21. Epub 2003 Mar 31. Erratum in: N Engl J Med. 2003 May 29;348(22):2271.

6.

Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis.

Pitt B, Rossignol P.

J Am Coll Cardiol. 2014 Feb 18;63(6):537-8. doi: 10.1016/j.jacc.2013.09.057. Epub 2013 Oct 30. No abstract available.

7.

Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).

Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B; EMPHASIS-HF Investigators.

J Am Coll Cardiol. 2013 Oct 22;62(17):1585-93. doi: 10.1016/j.jacc.2013.04.086. Epub 2013 Jun 27.

8.

Spironolactone in chronic hemodialysis patients improves cardiac function.

Taheri S, Mortazavi M, Shahidi S, Pourmoghadas A, Garakyaraghi M, Seirafian S, Eshaghian A, Ghassami M.

Saudi J Kidney Dis Transpl. 2009 May;20(3):392-7.

9.

Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.

Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R.

Am J Kidney Dis. 2008 Sep;52(3):501-6. doi: 10.1053/j.ajkd.2008.04.031. Epub 2008 Jul 24.

PMID:
18653268
10.

Long-term effects of spironolactone in peritoneal dialysis patients.

Ito Y, Mizuno M, Suzuki Y, Tamai H, Hiramatsu T, Ohashi H, Ito I, Kasuga H, Horie M, Maruyama S, Yuzawa Y, Matsubara T, Matsuo S; Nagoya Spiro Study Group.

J Am Soc Nephrol. 2014 May;25(5):1094-102. doi: 10.1681/ASN.2013030273. Epub 2013 Dec 12.

11.

The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.

Quach K, Lvtvyn L, Baigent C, Bueti J, Garg AX, Hawley C, Haynes R, Manns B, Perkovic V, Rabbat CG, Wald R, Walsh M.

Am J Kidney Dis. 2016 Oct;68(4):591-598. doi: 10.1053/j.ajkd.2016.04.011. Epub 2016 Jun 3. Review.

12.

Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients.

Matsumoto Y, Kageyama S, Yakushigawa T, Arihara K, Sugiyama T, Mori Y, Sugiyama H, Ohmura H, Shio N.

Cardiology. 2009;114(1):32-8. doi: 10.1159/000210553. Epub 2009 Apr 3.

PMID:
19342857
13.

Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.

Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA; CHARM Investigators.

Eur J Heart Fail. 2008 Feb;10(2):157-63. doi: 10.1016/j.ejheart.2007.12.006. Epub 2008 Jan 31.

14.

Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa).

Hammer F, Krane V, Störk S, Röser C, Hofmann K, Pollak N, Allolio B, Wanner C.

Nephrol Dial Transplant. 2014 Feb;29(2):400-5. doi: 10.1093/ndt/gft409. Epub 2013 Oct 28.

PMID:
24166468
15.

Effect of spironolactone in CV mortality in hemodialysis patients.

Kannan A, Poongkunran C, Balamuthusamy S.

J Am Coll Cardiol. 2014 Aug 5;64(5):528-9. doi: 10.1016/j.jacc.2014.03.053. No abstract available.

17.

Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.

Krum H, Mohacsi P, Katus HA, Tendera M, Rouleau JL, Fowler MB, Coats AJ, Roecker EB, Packer M; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.

Am Heart J. 2006 Jan;151(1):55-61.

PMID:
16368292
18.

Race influences the safety and efficacy of spironolactone in severe heart failure.

Vardeny O, Cavallari LH, Claggett B, Desai AS, Anand I, Rossignol P, Zannad F, Pitt B, Solomon SD; Randomized Aldactone Evaluation Study (RALES) Investigators.

Circ Heart Fail. 2013 Sep 1;6(5):970-6. doi: 10.1161/CIRCHEARTFAILURE.113.000530. Epub 2013 Aug 12.

19.

Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients.

Feniman-De-Stefano GM, Zanati-Basan SG, De Stefano LM, Xavier PS, Castro AD, Caramori JC, Barretti P, Franco RJ, Martin LC.

Ther Adv Cardiovasc Dis. 2015 Aug;9(4):158-67. doi: 10.1177/1753944715591448. Epub 2015 Jun 26.

PMID:
26116627
20.

Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.

Gross E, Rothstein M, Dombek S, Juknis HI.

Am J Kidney Dis. 2005 Jul;46(1):94-101.

PMID:
15983962

Supplemental Content

Support Center